End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
237.2 CNY | +0.67% | +4.33% | -1.96% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- With an expected P/E ratio at 42.72 and 36.24 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.96% | 19.77B | C | ||
+29.68% | 699B | C+ | ||
+25.07% | 571B | B | ||
-4.35% | 364B | C+ | ||
+17.65% | 326B | B- | ||
+3.77% | 286B | C+ | ||
+14.68% | 236B | B+ | ||
+4.71% | 198B | B- | ||
-12.43% | 194B | A+ | ||
-3.79% | 154B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600436 Stock
- Ratings Zhangzhou Pientzehuang Pharmaceutical., Ltd